Literature DB >> 2341727

Regulation of natural killer progenitors. Studies with a novel immunomodulator with distinct effects at the precursor level.

T Kalland1.   

Abstract

NK cells originate from progenitors in the bone marrow and maturate independently of other lymphoid organs. NK cell maturation represents an important site for regulation of the level of NK activity and constitutes a potentially interesting target for therapeutic intervention. The effect of the immunomodulator Linomide (carboxamide-3-quinoline) on the regeneration of NK cells was studied in vivo after depletion of mature NK cells. Linomide significantly, although to various extent, accelerated the maturation of NK cells after specific depletion with antibodies to asialomonoganglioside, treatment with cyclophosphamide or lethal irradiation and syngeneic bone marrow grafting. Examination of the target cell spectrum lysed by spleen effector cells during Linomide treatment as well as studies of phenotype, clearly indicated that the effector cells studied were NK cells. Treatment of mice for 4 days with Linomide increased the frequency of bone marrow NK cell progenitors from 1/11,900 to 1/6,000 as judged by limiting dilution analysis. Direct addition of Linomide in vitro had no effect on cultures of mature NK cells from spleen, but had an additive effect to IL-2 on the generation of NK cells when added to bone marrow cultures. Our study indicates that different mechanisms exist for the regulation of progenitor and mature NK cells, and that the immunomodulator Linomide represent a potentially important tool for investigating the mechanisms governing NK cell maturation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2341727

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  5 in total

Review 1.  Promising approaches in acute leukemia.

Authors:  J Cortes; H M Kantarjian
Journal:  Invest New Drugs       Date:  2000-02       Impact factor: 3.850

2.  Effect of a glucan, sizofiran, on natural-killer activity of 5-fluorouracil-treated murine bone marrow cells.

Authors:  Y Tsuchiya; M Matsutani; M Inoue; S Sato; T Asano; M Yajima
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

3.  Prevention of diabetes mellitus in non-obese diabetic mice by Linomide, a novel immunomodulating drug.

Authors:  D J Gross; H Sidi; L Weiss; T Kalland; E Rosenmann; S Slavin
Journal:  Diabetologia       Date:  1994-12       Impact factor: 10.122

4.  A feasibility study of roquinimex (Linomide) and alpha interferon in patients with advanced malignant melanoma or renal carcinoma.

Authors:  M J Mackean; D Kerr; M Lesko; A Svedberg; F Hansson; D Jodrell; J Cassidy
Journal:  Br J Cancer       Date:  1998-12       Impact factor: 7.640

5.  Enhanced lymphokine-activated killer cell activity by an immunomodulator, Roquinimex.

Authors:  F Vaz; M R Silva; J L Ascensao
Journal:  Br J Cancer       Date:  1995-12       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.